Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $53.77 | 1 | 77.9% |
| Education | $15.27 | 1 | 22.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Ortho Dermatologics, a division of Bausch Health US, LLC | $53.77 | 1 | $0 (2022) |
| PFIZER INC. | $15.27 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $15.27 | 1 | PFIZER INC. ($15.27) |
| 2022 | $53.77 | 1 | Ortho Dermatologics, a division of Bausch Health US, LLC ($53.77) |
All Payment Transactions
2 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 03/09/2023 | PFIZER INC. | CIBINQO (Drug) | Education | In-kind items and services | $15.27 | General |
| Category: Inflammation & Immunology | ||||||
| 10/20/2022 | Ortho Dermatologics, a division of Bausch Health US, LLC | DUOBRII (Drug) | Food and Beverage | In-kind items and services | $53.77 | General |
| Category: Dermatology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 772 | 1,050 | $110,004 | $46,086 |
| 2022 | 12 | 1,241 | 1,757 | $171,073 | $74,277 |
| 2021 | 12 | 1,451 | 2,192 | $231,205 | $100,469 |
| 2020 | 12 | 794 | 1,048 | $102,766 | $40,609 |
All Medicare Procedures & Services
48 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 213 | 239 | $26,290 | $13,185 | 50.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 78 | 89 | $14,329 | $7,225 | 50.4% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 133 | 146 | $17,374 | $5,471 | 31.5% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 66 | 74 | $12,580 | $5,066 | 40.3% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 63 | 67 | $13,266 | $4,809 | 36.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 38 | 38 | $9,976 | $3,563 | 35.7% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 29 | 29 | $4,669 | $1,660 | 35.5% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 86 | 292 | $3,212 | $1,476 | 46.0% |
| 11104 | Punch biopsy, first skin growth | Office | 2023 | 14 | 14 | $2,996 | $1,170 | 39.0% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2023 | 14 | 24 | $2,208 | $969.80 | 43.9% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 24 | 24 | $1,536 | $803.96 | 52.3% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2023 | 14 | 14 | $1,568 | $687.36 | 43.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 309 | 340 | $37,400 | $19,365 | 51.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 122 | 143 | $23,023 | $11,815 | 51.3% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2022 | 137 | 146 | $24,820 | $10,031 | 40.4% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 232 | 260 | $30,940 | $9,775 | 31.6% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2022 | 98 | 107 | $21,186 | $8,352 | 39.4% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 52 | 52 | $8,372 | $3,532 | 42.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 28 | 28 | $7,435 | $2,911 | 39.2% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2022 | 152 | 561 | $6,171 | $2,823 | 45.7% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 60 | 61 | $3,904 | $2,287 | 58.6% |
| 11104 | Punch biopsy, first skin growth | Office | 2022 | 17 | 17 | $3,638 | $1,551 | 42.6% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2022 | 18 | 26 | $2,392 | $1,054 | 44.0% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2022 | 16 | 16 | $1,792 | $780.91 | 43.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 221 | 267 | $29,370 | $17,296 | 58.9% |
About Dr. Julie Lin, MD
Dr. Julie Lin, MD is a Dermatology healthcare provider based in Saint Albans, Vermont. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/11/2006. The National Provider Identifier (NPI) number assigned to this provider is 1063572907.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Julie Lin, MD has received a total of $69.04 in payments from pharmaceutical and medical device companies, with $15.27 received in 2023. These payments were reported across 2 transactions from 2 companies. The most common payment nature is "Food and Beverage" ($53.77).
As a Medicare-enrolled provider, Lin has provided services to 4,258 Medicare beneficiaries, totaling 6,047 services with total Medicare billing of $261,441. Data is available for 4 years (2020–2023), covering 48 distinct procedure/service records.
Practice Information
- Specialty Dermatology
- Other Specialties Dermatology
- Location Saint Albans, VT
- Active Since 12/11/2006
- Last Updated 09/22/2020
- Taxonomy Code 207N00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1063572907
Products in Payments
- DUOBRII (Drug) $53.77
- CIBINQO (Drug) $15.27
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.